The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder-Reference-Cited by-同舟云学术

The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder

Published:2022-06-08 Issue:11 Volume:88 Page:4828-4838
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Nasser Azmi¹^ORCID,Gomeni Roberto²,Wang Zhao¹,Hull Joseph T.¹,Busse Gregory D.³,Melyan Zare³,Fava Maurizio⁴,O'Neal Welton¹,Rubin Jonathan¹

Affiliation:

1. Supernus Pharmaceuticals, Inc. Rockville MD USA

2. Pharmacometrica, Lieu‐dit Longcol, La Fouillade France

3. Formerly with Supernus Pharmaceuticals, Inc. Rockville MD USA

4. Department of Psychiatry Massachusetts General Hospital Boston MA USA

Funder

Supernus Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15412

Reference29 articles.

1. Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

2. U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER).Major Depressive Disorder: Developing Drugs for Treatment Guidance for Industry. June2018. Revision 1.

3. Placebo Response and Antidepressant Clinical Trial Outcome

4. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents;Expert Review of Neurotherapeutics;2024-03-19